| Literature DB >> 30872156 |
Ali Alikhan1, Christopher Sayed2, Afsaneh Alavi3, Raed Alhusayen3, Alain Brassard4, Craig Burkhart5, Karen Crowell6, Daniel B Eisen4, Alice B Gottlieb7, Iltefat Hamzavi8, Paul G Hazen9, Tara Jaleel10, Alexa B Kimball11, Joslyn Kirby12, Michelle A Lowes13, Robert Micheletti14, Angela Miller8, Haley B Naik15, Dennis Orgill16, Yves Poulin17.
Abstract
Hidradenitis suppurativa is a chronic inflammatory disorder affecting hair follicles, with profoundly negative impact on patient quality of life. Evidence informing ideal evaluation and management of patients with hidradenitis suppurativa is still sparse in many areas, but it has grown substantially in the last decade. Part I of this evidence-based guideline is presented to support health care practitioners as they select optimal management strategies, including diagnostic testing, comorbidity screening, and both complementary and procedural treatment options. Recommendations and evidence grading based on the evidence available at the time of the review are provided.Entities:
Keywords: Nd:YAG; acne inversa; adalimumab; biomarkers; carbon dioxide laser; clindamycin; comorbidities; ertapenem; finasteride; guidelines; hidradenitis suppurativa; infliximab; laser; lifestyle modification; microbiome; oral contraceptive pills; rifampin; spironolactone
Mesh:
Substances:
Year: 2019 PMID: 30872156 PMCID: PMC9131894 DOI: 10.1016/j.jaad.2019.02.067
Source DB: PubMed Journal: J Am Acad Dermatol ISSN: 0190-9622 Impact factor: 15.487